keyword
MENU ▼
Read by QxMD icon Read
search

peramivir

keyword
https://www.readbyqxmd.com/read/29082897/peramivir-susceptibilities-of-recombinant-influenza-a-and-b-variants-selected-with-various-neuraminidase-inhibitors
#1
Clément Fage, Véronique Tu, Julie Carbonneau, Yacine Abed, Guy Boivin
BACKGROUND: Peramivir is a parenteral neuraminidase inhibitor (NAI) approved for treating influenza infections in a few countries. We determined peramivir susceptibilities of several uncharacterized influenza A and B neuraminidase (NA) and haemagglutinin (HA) mutants selected with different NAIs. METHODS: Recombinant wild-type (WT) and mutant NA proteins were expressed in 293T cells and susceptibility to peramivir, oseltamivir and zanamivir was determined by NA inhibition assay using the MUNANA substrate...
March 22, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/29063410/discovery-of-potent-neuraminidase-inhibitors-using-a-combination-of-pharmacophore-based-virtual-screening-and-molecular-simulation-approach
#2
Rohini K, Shanthi V
Neuraminidase (NA), a surface protein, facilitates the release of nascent virus and thus spreads infection. It has been renowned as a potential drug target for influenza A virus infection. The drugs such as oseltamivir, zanamivir, peramivir, and laninamivir are approved for the treatment of influenza infection. Additionally, investigational drugs namely MK2206, tamiphosphor, crenatoside, and dehydroepiandrosterone (DHEA) are also available for the treatment. However, recent outbreaks of highly pathogenic and drug-resistant influenza A strains highlighted the need to discover novel NA inhibitor...
October 23, 2017: Applied Biochemistry and Biotechnology
https://www.readbyqxmd.com/read/29046464/screening-for-neuraminidase-inhibitor-resistance-markers-among-avian-influenza-viruses-of-the-n4-n5-n6-and-n8-neuraminidase-subtypes
#3
Won-Suk Choi, Ju Hwan Jeong, Jin Jung Kwon, Su Jeong Ahn, Khristine Kaith S Lloren, Hyeok-Il Kwon, Hee Bok Chae, Jungwon Hwang, Myung Hee Kim, Chul-Joong Kim, Richard J Webby, Elena A Govorkova, Young Ki Choi, Yun Hee Baek, Min-Suk Song
Several subtypes of avian influenza viruses (AIVs) are emerging as novel human pathogens, and the frequency of related infections has increased in recent years. Although neuraminidase (NA) inhibitors (NAIs) are the only class of antiviral drugs available for therapeutic intervention for AIV-infected patients, studies on NAI resistance among AIVs have been limited and markers of resistance are poorly understood. Previously, we identified unique NAI-resistance substitutions in AIVs of N3, N7, and N9 NA subtypes...
October 18, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28976569/hplc-ms-ms-analysis-of-peramivir-in-rat-plasma-elimination-of-matrix-effect-using-the-phospholipid-removal-solid-phase-extraction-method
#4
Mingdao Lei, Wei Gan, Yongbing Sun
A simple HPLC-MS/MS method has been developed for the determination of peramivir in rat plasma in the present study. The analytes were separated on a C18 column (50×2.1mm, 1.7 μm) and a triple-quadrupole mass spectrometry equipped with an electrospray ionization (ESI) source was applied for the detection. A phospholipid-free cartridge SPE was used to pretreat the plasma and eliminate the endogenous phospholipid. The in-source collisionally induced dissociation (CID) approach showed that this pretreatment could result in the negligible ion suppression from the extracted sample, and could bring cleaner samples when compared with the protein precipitation...
October 4, 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/28934455/drug-susceptibility-evaluation-of-an-influenza-a-h7n9-virus-by-analyzing-recombinant-neuraminidase-proteins
#5
Larisa V Gubareva, Katrina Sleeman, Zhu Guo, Hua Yang, Erin Hodges, Charles T Davis, Tatiana Baranovich, James Stevens
Background: Neuraminidase (NA) inhibitors are the recommended antiviral medications for influenza treatment. However, their therapeutic efficacy can be compromised by NA changes that emerge naturally and/or following antiviral treatment. Knowledge of which molecular changes confer drug resistance of influenza A(H7N9) viruses (group 2NA) remains sparse. Methods: Fourteen amino acid substitutions were introduced into the NA of A/Shanghai/2/2013(H7N9). Recombinant N9 (recN9) proteins were expressed in a baculovirus system in insect cells and tested using the Centers for Disease Control and Prevention standardized NA inhibition (NI) assay with oseltamivir, zanamivir, peramivir, and laninamivir...
September 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28869418/a-meta-analysis-of-laninamivir-octanoate-for-treatment-and-prophylaxis-of-influenza
#6
Masayoshi Higashiguchi, Tomoshige Matsumoto, Takashi Fujii
BACKGROUND: Laninamivir octanoate is a recently developed inhaled neuraminidase inhibitor for treating influenza virus infection. We performed meta-analyses to clarify the efficacy of laninamivir octanoate on influenza treatment and prevention. METHODS: MEDLINE and CENTRAL were searched to identify eligible studies. The log median time to event ratios (logMRs) and log odds ratios (logORs) were combined with meta-analysis. RESULTS: Nine studies in treatment settings and three studies in prophylaxis settings were eligible for this meta-analysis...
September 4, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28802866/global-update-on-the-susceptibility-of-human-influenza-viruses-to-neuraminidase-inhibitors-2015-2016
#7
Larisa V Gubareva, Terry G Besselaar, Rod S Daniels, Alicia Fry, Vicki Gregory, Weijuan Huang, Aeron C Hurt, Patricia A Jorquera, Angie Lackenby, Sook-Kwan Leang, Janice Lo, Dmitriy Pereyaslov, Helena Rebelo-de-Andrade, Marilda M Siqueira, Emi Takashita, Takato Odagiri, Dayan Wang, Wenqing Zhang, Adam Meijer
Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) assessed antiviral susceptibility of 14,330 influenza A and B viruses collected by WHO-recognized National Influenza Centres (NICs) between May 2015 and May 2016. Neuraminidase (NA) inhibition assay was used to determine 50% inhibitory concentration (IC50) data for NA inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir...
August 10, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28761899/efficacy-and-safety-of-intravenous-peramivir-compared-with-oseltamivir-in-high-risk-patients-infected-with-influenza-a-and-b-viruses-a-multicenter-randomized-controlled-study
#8
Shigeki Nakamura, Taiga Miyazaki, Koichi Izumikawa, Hiroshi Kakeya, Yutaka Saisho, Katsunori Yanagihara, Yoshitsugu Miyazaki, Hiroshi Mukae, Shigeru Kohno
BACKGROUND: Clinical studies comparing the different neuraminidase inhibitors for treatment of at-risk patients with influenza have not been performed. To optimize such treatments, we assessed the efficacy and safety of intravenous peramivir compared with oral oseltamivir in treating seasonal influenza A or B virus infection. METHODS: A multicenter, randomized, controlled clinical trial was conducted from December 2012 to May 2014 in high-risk patients infected with seasonal influenza...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28720319/safety-and-efficacy-of-anti-influenza-drugs-intravenous-peramivir-against-influenza-virus-infection-in-elderly-patients-with-underlying-disease
#9
Kazufumi Takamatsu, Satoshi Marumo, Motonari Fukui, Atsuko Hata
We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4-40.6). Results confirm intravenous peramivir's usefulness.
August 2017: Journal of Microbiology, Immunology, and Infection, Wei Mian Yu Gan Ran za Zhi
https://www.readbyqxmd.com/read/28717095/encephalopathy-associated-with-influenza-b-in-a-healthy-young-man
#10
Masaki Shimamoto, Satoshi Okada, Takeshi Terashima
A 19-year-old man presented with a fever, convulsions, and loss of consciousness at our hospital. The patient had a Glasgow Coma Scale score of 12. Influenza B virus infection was diagnosed using the rapid test kit, and an eight-fold increase in the serum levels of anti-influenza B virus antibody was confirmed using the complement fixation test. Brain magnetic resonance imaging showed multifocal high-signal lesions, and an electroencephalogram showed diffuse slowing of the background activity, indicating acute encephalopathy...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28716363/clinical-outcomes-and-prognostic-factors-of-patients-with-severe-influenza-receiving-intravenous-peramivir-salvage-therapy-in-intensive-care-units
#11
Ching-Yuan Yeh, Fu-Der Wang, Yu-Chung Chuang, Chia-Jui Yang, Shiang-Fen Huang, Wen-Sung Weng, Chun-Hsin Liaw, Wang-Huei Sheng
BACKGROUND: Few studies have investigated patients with severe influenza who receive intravenous peramivir for salvage therapy. METHODS: We retrospectively analyzed data from 71 patients with severe influenza who received intravenous peramivir therapy in the intensive care units of three medical centers between 2012 and 2016. All patients received oseltamivir or zanamivir before the administration of peramivir. RESULTS: A total of 44 men and 27 women with a median age of 55 years were enrolled...
June 26, 2017: Journal of Microbiology, Immunology, and Infection, Wei Mian Yu Gan Ran za Zhi
https://www.readbyqxmd.com/read/28663940/considerations-for-use-of-investigational-drugs-in-public-health-emergencies
#12
Matthew Carl Kirchoff, Jerome F Pierson
The paradigm for the use of investigational drugs in public health emergencies has been recently tested to prevent and treat highly infectious and lethal diseases. Examples include the successful implementation of vaccine and therapeutic clinical trials during the recent Ebola outbreak in West Africa. On the other end of the spectrum was the Emergency Use Authorization (EUA) of peramivir in the treatment of H1N1 influenza virus that did not provide an opportunity to collect data or understand the effectiveness of the EUA program...
March 2017: Therapeutic Innovation & Regulatory Science
https://www.readbyqxmd.com/read/28540991/comparison-of-efficacy-of-intravenous-peramivir-and-oral-oseltamivir-for-the-treatment-of-influenza-systematic-review-and-meta-analysis
#13
REVIEW
Jonghoo Lee, Ju Hee Park, Hyeyoung Jwa, Yee Hyung Kim
PURPOSE: Peramivir is the first intravenously administered neuramidase inhibitor for immediate delivery of an effective single-dose treatment in patients with influenza. However, limited data are available on intravenous (IV) peramivir treatment compared to oral oseltamivir for these patients. MATERIALS AND METHODS: With a systematic review and meta-analysis, we compared the efficacy of IV peramivir with oral oseltamivir for treatment of patients with seasonal influenza...
July 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28337082/pharmacokinetics-of-peramivir-in-an-adolescent-patient-receiving-continuous-venovenous-hemodiafiltration
#14
Ryan C Dillon, Robert Witcher, Jeffrey J Cies, Wayne S Moore, Arun Chopra
Critically ill patients requiring renal replacement therapy commonly experience pharmacokinetic alterations. This case report describes the pharmacokinetics of peramivir (Rapivab, BioCryst Pharmaceuticals, Inc, Durham, NC), the first US Food and Drug Administration-approved intravenous neuraminidase inhibitor for the treatment of influenza, in an adolescent patient receiving continuous renal replacement therapy (CRRT). A 49.5-kg, 17-year-old Caucasian female presented with fever, cough, and persistent hypoxia...
January 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/28272019/geniposide-demonstrates-anti-inflammatory-and-antiviral-activity-against-pandemic-a-jiangsu-1-2009-h1n1-influenza-virus-infection-in-vitro-and-in-vivo
#15
Zhang Yunshi, Yao Jing, Qi Xian, Liu Xing, Lu Xieqin, Feng Ganzhu
BACKGROUND: Influenza A viruses (IAVs) remains to be a great threat to human health for centuries, without effective control. Geniposide, a main iridoid glycoside compound extracted from Gardenia jasminoides Ellis (GJ) fruit, possesses various biologic activities including anti-inflammation and anti-virus. METHODS: Madin-Darby Canine Kidney (MDCK) cells were infected with pandemic A/Jiangsu/1/2009 (H1N1) influenza virus in vitro. Cytotoxicity and antiviral activity of geniposide were estimated by MTT assay...
March 8, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28236410/screening-and-evaluation-of-commonly-used-anti-influenza-chinese-herbal-medicines-based-on-anti-neuraminidase-activity
#16
Xue Han, Ding-Kun Zhang, Yu-Ming Guo, Wu-Wen Feng, Qin Dong, Cong-En Zhang, Yong-Feng Zhou, Yan Liu, Jia-Bo Wang, Yan-Ling Zhao, Xiao-He Xiao, Ming Yang
Anti-influenza Chinese herbal medicines (anti-flu CHMs) have advantages in preventing and treating influenza virus infection. Despite various data on antiviral activities of some anti-flu CHMs have been reported, most of them could not be compared using the standard evaluation methods for antiviral activity. This situation poses an obstacle to a wide application of anti-flu CHMs. Thus, it was necessary to develop an evaluation method to estimate antiviral activities of anti-flu CHMs. In the present study, we searched for anti-flu CHMs, based on clinic usage, to select study objects from commonly-used patented anti-flu Chinese medicines...
October 2016: Chinese Journal of Natural Medicines
https://www.readbyqxmd.com/read/28195559/selection-of-multi-drug-resistant-influenza-a-and-b-viruses-under-zanamivir-pressure-and-their-replication-fitness-in-ferrets
#17
Ding Yuan Oh, Jacqueline Panozzo, Sophie Vitesnik, Rubaiyea Farrukee, David Piedrafita, Jennifer Mosse, Aeron C Hurt
BACKGROUND: Intravenous zanamivir has been used to treat patients with severe influenza. Because the majority of cases (including immunocompromised patients) require the drug for an extended period of treatment, there is a higher risk that the virus will develop resistance. Therefore, knowing the possible amino acid substitutions that may arise in recently circulating influenza strains under prolonged zanamivir exposure and their impact on antiviral susceptibility is important. METHODS: Influenza A(H1N1)pdm09, A(H3N2) and B virus were serially passaged under increasing zanamivir pressure in vitro...
February 14, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28012921/therapeutic-efficacy-of-peramivir-against-h5n1-highly-pathogenic-avian-influenza-viruses-harboring-the-neuraminidase-h275y-mutation
#18
Masanori Kobayashi, Makoto Kodama, Takeshi Noshi, Ryu Yoshida, Takushi Kanazu, Naoki Nomura, Kosuke Soda, Norikazu Isoda, Masatoshi Okamatsu, Yoshihiro Sakoda, Yoshinori Yamano, Akihiko Sato, Hiroshi Kida
High morbidity and mortality associated with human cases of highly pathogenic avian influenza (HPAI) viruses, including H5N1 influenza virus, have been reported. The purpose of the present study was to evaluate the antiviral effects of peramivir against HPAI viruses. In neuraminidase (NA) inhibition and virus replication inhibition assays, peramivir showed strong inhibitory activity against H5N1, H7N1 and H7N7 HPAI viruses with sub-nanomolar activity in enzyme assays. In H5N1 viruses containing the NA H275Y mutation, the antiviral activity of peramivir against the variant was lower than that against the wild-type...
December 22, 2016: Antiviral Research
https://www.readbyqxmd.com/read/28000173/in-vitro-evaluation-of-absorption-characteristics-of-peramivir-for-oral-delivery
#19
Ying Li, Zhiyuan Wang, Xin Li, Wei Gong, Xiangyang Xie, Yang Yang, Wu Zhong, Aiping Zheng
BACKGROUND AND OBJECTIVE: Peramivir is a novel antiviral agent approved for the treatment of severe influenza. However, the development of oral formulation of peramivir has been severely hurdled by poor bioavailability (human, ≤3%). The present work aims to evaluate oral permeability characteristics of peramivir. METHODS: In vitro gastrointestinal stability, metabolic stability in human intestinal S9 fraction and Caco-2 permeability were performed. The liquid chromatography with tandem mass spectrometric (LC-MS/MS) was used to quantify peramivir in buffer and biological sample...
December 21, 2016: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/27898328/fate-of-new-three-anti-influenza-drugs-and-one-prodrug-in-the-water-environment
#20
Takashi Azuma, Mao Ishida, Kanae Hisamatsu, Ayami Yunoki, Kana Otomo, Mari Kunitou, Mai Shimizu, Kaori Hosomaru, Shiori Mikata, Yoshiki Mino
We evaluated the environmental fate of new three anti-influenza drugs, favipiravir (FAV), peramivir (PER), and laninamivir (LAN), and an active prodrug of LAN, laninamivir octanoate (LANO), in comparison with four conventional drugs, oseltamivir (OS), oseltamivir carboxylate (OC), amantadine (AMN), and zanamivir (ZAN) by photodegradation, biodegradation, and sorption to river sediments. In addition, we conducted 9-month survey of urban rivers in the Yodo River basin from 2015 to 2016 (including the influenza season) to investigate the current status of occurrence of these drugs in the river environment...
February 2017: Chemosphere
keyword
keyword
57476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"